News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Immunotherapy drug for skin disease could boost hormone treatment for prostate cancer
A new form of immunotherapy reactivates the response to hormone treatment in advanced prostate cancer, a study in mice and human prostate cancer cells has found.
ICR and partners take centre stage at major international conferences
Clinical trials of promising cancer treatments discovered or developed at the ICR were among the highlights at this year’s American Society of Clinical Oncology (ASCO) meeting, the biggest international clinical cancer research gathering of the year.
Professor Mel Greaves awarded prestigious Society of Memorial Sloan Kettering Prize for contributions to childhood cancer
The ICR’s Professor Mel Greaves has been awarded a prestigious prize from the Memorial Sloan Kettering Cancer Center in New York for his ground-breaking research and expertise in childhood leukaemia.
Higher BMI is associated with a lower risk of breast cancer before the menopause
Having a higher body mass index (BMI) at a younger age is associated with a decreased risk of developing breast cancer before the menopause, major new research funded by Breast Cancer Now and other collaborators has found.
ICR ranked among the world’s best research institutions for industry collaboration
The ICR has ranked in the top 30 higher education institutions in the world for research in an independent evaluation funded by the European Commission.
Gene testing could identify men with prostate cancer who may benefit from immunotherapy
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.
Blocking energy production could help treat lung cancer where chemotherapy has limited effect
Targeting an enzyme that helps cells to generate energy could trigger cell death and be a way to treat some forms of lung cancer, even where the effect of chemotherapy is limited.
Prostate cancer DNA test identifies men with six-fold increased risk
A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer.
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (brand name Zytiga) will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS.
Stunting cell ‘antennae’ could make cancer drugs work again
Scientists have uncovered a completely new way to make cancers sensitive to treatment – by targeting antenna-like structures on cells.
ASCO 2018: Major trial is first to show benefits of immunotherapy in some men with prostate cancer
A major clinical trial has become the first to show benefits of immunotherapy in prostate cancer – for some men with advanced, otherwise untreatable disease.
Acclaimed opera singers come together to support the ICR
A world-class group of opera singers united at the intimate setting of Spencer House this week to celebrate and support the ICR.
